Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTROL
NCT05802056Phase 1Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Nov 2023
- Primary completion
- Apr 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldesleukin in gastric cancer (GC), sponsored by Mayo Clinic. Primary endpoints: Peritoneal Carcinomatosis Index at 90 days and Adverse Events at 90 days. Started Nov 2023; status: active, not recruiting.
02
Drugs
aldesleukin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05802056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802056.